Description:
An impurity of Parecoxib. The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue. Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision.
- Molecular Weight:384.45
- Purity:95%
Molecular Formula:
C20H20N2O4S
Canonical SMILES:
CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)NC(=O)C(C)C
InChI:
InChI=1S/C20H20N2O4S/c1-13(2)20(23)22-27(24,25)17-11-9-15(10-12-17)18-14(3)26-21-19(18)16-7-5-4-6-8-16/h4-13H,1-3H3,(H,22,23)
InChIKey:
SHEZNOJEXCHKRT-UHFFFAOYSA-N
Solubility:
Soluble in DMSO
Appearance:
Solid
Storage: -20°C
Synonyms:
N-((4-(5-Methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)isobutyramide; 2-methyl-N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; Propanamide, 2-methyl-N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-; SCHEMBL5069872; DTXSID50627261; AS-80624; CS-0255351; F83303; 2-Methyl-N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide; 2-Methyl-N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonyl]propanamide; 2-METHYL-N-[4-(5-METHYL-3-PHENYL-1,2-OXAZOL-4-YL)BENZENESULFONYL]PROPANAMIDE; N-((4-(5-Methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)isobutyramide (Palbociclib Impurity) Más detalles se encuentran
aquí